UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of May, 2021
Commission File Number: 001-38283
InflaRx N.V.
(Translation of registrant's name into English)
Winzerlaer Str. 2
07745 Jena, Germany
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFLARX N.V.
Results of Annual General Meeting of Shareholders
On May 19, 2021, InflaRx N.V. (“InflaRx”) held its Annual General Meeting of Shareholders (the “Annual General Meeting”). The final results of each of the agenda items
submitted to a vote of the shareholders are as follows:
Agenda Item 3. Adoption of the Dutch statutory annual accounts for the fiscal year ended December 31, 2020.
InflaRx shareholders approved the adoption of the Dutch statutory annual accounts for the fiscal year ended December 31, 2020.
Agenda Item 5. Instruction to Ernst & Young Accountants LLP for the external audit of InflaRx’s annual accounts for the financial
year 2021.
InflaRx shareholders approved the instruction to Ernst & Young Accountants LLP for the external audit of InflaRx’s annual
accounts for the financial year 2021.
Agenda Item 6. Release from liability for InflaRx’s directors with respect to the performance of their duties during the fiscal year
ended December 31, 2020.
InflaRx shareholders approved the release from liability for InflaRx’s directors with respect to the performance of their duties
during the fiscal year ended December 31, 2020.
Agenda Item 7. Re-appointment of Mr. Mark Kübler as non-executive director of InflaRx.
InflaRx shareholders approved the re-appointment of Mr. Mark Kübler as non-executive director of InflaRx.
Agenda Item 8. Re-appointment of Ms. Lina Ma as non-executive director of InflaRx.
InflaRx shareholders approved the re-appointment of Ms. Lina Ma as non-executive director of InflaRx.
Agenda Item 9. Appointment of Mr. Anthony Gibney as non-executive director of InflaRx.
InflaRx shareholders approved the appointment of Mr. Anthony Gibney as non-executive director of InflaRx.
Agenda Item 10. Extension of authorization for InflaRx’s board of directors (the “Board”) to
issue shares and grant rights to subscribe for shares.
InflaRx shareholders approved the extension of authorization for the Board to issue shares and grant rights to subscribe for share.
Agenda Item 11. Extension of authorization for the Board to limit and exclude pre-emption rights.
InflaRx shareholders approved the extension of authorization for the Board to limit and exclude pre-emption rights.
Agenda Item 12. Extension of authorization for the Board to acquire shares and depository receipts for shares in InflaRx’s capital.
InflaRx shareholders approved the extension of authorization for the Board to acquire shares and depository receipts for shares in InflaRx’s
capital.
Appointment of Anthony Gibney as Non-Executive Director
On May 21, 2021, following shareholder approval at the Annual General Meeting, Anthony Gibney was appointed as a non-executive director of InflaRx. InflaRx issued a press release titled “Tony Gibney Joins InflaRx Board
of Directors.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
INFLARX N.V.
|
|
|
Date: May 21, 2020
|
By:
|
|
/s/ Niels Riedemann
|
|
Name:
|
Niels Riedemann
|
|
Title:
|
Chief Executive Officer
|
EXHIBIT INDEX
|
|
|
|
|
Press Release, dated May 21, 2021
|